FDC Limited (BOM:531599)
India · Delayed Price · Currency is INR 354.40
+0.10 (0.03%)
At close: Aug 17, 2026
FDC Limited Revenue
FDC Limited had revenue of 6.68B INR in the quarter ending June 30, 2026, with 2.97% growth. This brings the company's revenue in the last twelve months to 21.90B, up 3.40% year-over-year. In the fiscal year ending March 31, 2026, FDC Limited had annual revenue of 21.71B with 2.98% growth.
Revenue (ttm)
21.90B
Revenue Growth
+3.40%
P/S Ratio
2.63
Revenue / Employee
3.19M
Employees
6,857
Market Cap
57.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 21.71B | 628.13M | 2.98% |
| Mar 31, 2025 | 21.08B | 1.65B | 8.50% |
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viyash Scientific | 35.76B |
| Unichem Laboratories | 23.17B |
| Morepen Laboratories | 19.51B |
| Sanofi India | 18.05B |
| Hikal | 17.35B |
| Procter & Gamble Health | 14.33B |
| Bliss GVS Pharma | 10.05B |
| Gufic Biosciences | 9.81B |
FDC Limited News
- 2 months ago - FDC reports Rs 585 crore revenue in Q4 FY26 with 18.9% growth - Business Upturn
- 2 months ago - FDC reports 18.9% revenue growth in Q4 FY26, driven by strong export performance - Business Upturn
- 3 months ago - FDC Limited receives US FDA ANDA approval for Cefixime Oral Suspension — opens new revenue line in US antibiotic market - Business Upturn
- 5 months ago - FDC reconstitutes board committees and appoints Mohan Chandavarkar as chairman - Business Upturn
- 11 months ago - FDC receives ANDA approval from U.S. FDA for Pilocarpine Hydrochloride Ophthalmic Solution USP - Business Upturn
- 1 year ago - FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY - Business Upturn
- 1 year ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 2 years ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn